Carisma Therapeutics' Significant Contributions at SITC 2024
Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, is poised to make waves at the Society for Immunotherapy of Cancer (SITC) this year. The event is eagerly anticipated in the immuno-oncology community and Carisma is set to present innovative findings that could reshape treatment approaches for cancer.
Key Highlights of Poster Presentations
Details about the poster presentations reveal major advancements that Carisma has achieved in immunotherapy. The company focuses on creating unique therapies that utilize engineered macrophages and monocytes, which play essential roles in the body’s immune response against cancer.
First Presentation: Novel Anti-GPC3 CAR-M
One of the standout presentations is titled "Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma." This study emphasizes the promising results from preclinical trials, showcasing the potential of this CAR therapy in targeting specific cancer cells.
Second Presentation: First-in-Human Study of Anti-HER2 CAR
Another notable presentation discusses the "Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors." This innovative approach emphasizes autologous cell therapy, underscoring the trend towards personalized medicine in oncology.
Event Details and Accessibility
SITC 2024 will encompass significant sessions where Carisma's findings will be shared. Attendees can find their posters located at the Exhibit Halls A and B at the George R. Brown Convention Center, and following the presentation, all materials will be accessible through the "Publications" section on Carisma's official website.
About Carisma Therapeutics
Carisma Therapeutics is noted for its commitment to transforming cancer treatment through its innovative cell therapy platform. Utilizing engineered macrophages and monocytes, the company aims to pioneer immunotherapies designed to tackle serious diseases more effectively.
Investors and Media Relations
For stakeholders interested in further insights, Carisma maintains open channels through head of investor relations, Shveta Dighe, who can be contacted directly. Additionally, Julia Stern serves as the media contact, ensuring that inquiries are addressed promptly.
Frequently Asked Questions
What are the key focuses of Carisma Therapeutics?
Carisma is dedicated to developing innovative immunotherapies using its proprietary macrophage and monocyte cell engineering platform.
Where will Carisma present its research?
The research will be presented at the Society for Immunotherapy of Cancer (SITC) event held in Houston's George R. Brown Convention Center.
When can we view the posters presented?
The posters will be available online at Carisma's website in the Publications section following the event.
How does Carisma's therapy platform work?
The platform involves creating engineered immune cells, including macrophages and monocytes, to enhance the immune response against cancer.
Who can I contact for investor-related inquiries?
Investors can reach out to Shveta Dighe, the head of investor relations, for more details.
